Transcatheter mitral valve repair using the Cardioband® system:
Histopathological insights in device ingrowth and biocompatibility
Abstract
Surgical implantation of a complete or incomplete ring to reduce the
valve annulus and improve leaflet coaptation is the mainstay of mitral
valve surgery. The Cardioband® system (Edwards Lifesciences, Irvine, CA,
USA) was designed to address the pathophysiological mechanism of annular
dilatation through a catheter-based approach. We present the
histopathological workup of a Cardioband® device, which had been
implanted 21 months earlier in a 34-year-old male with ischemic
cardiomyopathy. Device examination demonstrate a well-positioned and
securely anchored device. The described tissue reactions may have an
impact on choice of device and timing in case of re-do surgery.